Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependent Health formulary changes: Coverage & P…
    Ask Trek AI about this page
    ModifiedIndependent HealthPolicy N/A

    Formulary (List of Covered Drugs) Changes

    Customize your policy alerts

    Sign up for all Independent Health policy alerts

    Know when Independent Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists upcoming and past changes to Independent Health commercial drug formularies and indicates affected drugs, change types, prior authorization, step therapy and alternatives; applies to Independent Health members across plans tracked in the document.

    Policy Summary
    PayerIndependent Health
    PolicyFormulary (List of Covered Drugs) Changes
    Policy CodePolicy N/A
    Change TypeMultiple NF and tier revisions with PA and ST adjustments
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for drugs flagged 'PA' before requesting coverage.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Stelara was removed from the formulary (changed to Non-Formulary) effective 7/1/2025.

    Victoza was removed from the formulary (changed to Non-Formulary) effective 10/1/2025.

    Multiple Revlimid (lenalidomide) tablet strengths (2.5, 5, 10, 15, 20, 25 mg) were removed from the formulary effective 10/1/2025.

    Jynarque (tolvaptan) product presentations were removed from the formulary effective 1/1/2026.

    Orladeyo (110 mg and 150 mg) was removed from the formulary effective 1/1/2026.

    A large number of branded biologics and biosimilars were changed to Non-Formulary effective 1/1/2026 with listed alternatives.

    Noxafil packet was removed from the formulary effective 1/1/2026.

    Dayvigo 5 mg was removed from the formulary effective 1/1/2026.

    Multiple drugs had tier assignments and PA requirements revised (e.g., Dayvigo 5mg moved from Tier 2 to Tier 3 with PA).

    Several hepatitis C products had tier changes (many from Tier 3 to Tier 2) and formulary group reassignment.

    Multiple specialty biologics and biosimilars (e.g., Abrilada, Cosentyx, Cimzia) had formulary tier/status/table information updated.

    Numerous opioid and analgesic extended-release products had tier reassignment with effective dates in March 2026.

    Certain CNS/sleep agents had tier changes and substitution mappings.

    Several generic and contraceptive products had tier changes and formulary group updates.

    Multiple branded and generic products moved from Tier 1 to Tier 3 and some were marked NF with effective date 3/1/2026 for specific items.

    A set of products (Sancuso patch; Relistor formulations; Symproic; Xarelto 2.5mg) are scheduled to change to Non‑Formulary on 7/1/2026.

    Numerous tier adjustments effective 9/1/2025 or 1/1/2026 for stimulant agents, dermatology agents, antifungals, and other drugs.

    Multiple drugs have updated tier assignments and/or Drug Formulary impacts effective on various dates (mostly 1/1/2026, 3/1/2026, or 7/1/2026).

    12+distinct drug groups becoming non-formulary
    1/1/2026most common effective date
    dozensproducts with tier/status changes
    multipleHep C moves Tier 3→2
    7/1/2026upcoming NF effective date

    Coverage Criteria and Formulary Status

    Products designated NF (Non‑Formulary) in the listings are excluded from coverage under the Independent Health formulary effective on the date shown for each entry. Examples in this document include a range of biologics, specialty agents and other branded products (e.g., Stelara effective 7/1/2025; multiple Revlimid strengths effective 10/1/2025; Jynarque and select Orladeyo presentations effective 1/1/2026; and multiple Humira and Abrilada presentations effective 1/1/2026), which are listed as NF and therefore will no longer be covered under the formulary after the listed effective date.

    When a product is moved to NF, the document includes any specified alternatives or therapeutic substitutions where provided (for example, alternatives listed for Stelara include Yesintek, Selarsdi, adalimumab, Otezla, Skyrizi, Taltz, Rinvoq, Xeljanz or Xeljanz XR; Revlimid entries list generic lenalidomide; Jynarque entries reference tolvaptan (generic Jynarque)), and indicates the impacted Drug Formulary(s). Requests for coverage of NF products may be denied unless a medical exception is approved.

    Non‑Formulary (NF)
    DefinitionNon‑Formulary (NF) — drugs removed from the formulary and no longer covered under the plan.
    Coverage implicationRequests for NF drugs may be denied under the formulary benefit unless a medical exception (prior authorization) is approved.
    AlternativesAn alternative formulary drug may be listed when a product becomes NF; discuss alternatives with the prescriber.
    Formulary substitution mapping examples
    ConceptSubstitution mapping — a listed product is associated with one or more preferred alternative agents to be used when the original product is changed or removed.
    Example 1Epclusa 150-37.5mg pack mapped to Mavyret, sofosbuvir-velpatasvir or ledipasvir-sofosbuvir (effective 1/1/2026).
    Example 2Sovaldi (150mg/200mg pack or tablet) mapped to Mavyret, sofosbuvir-velpatasvir or ledipasvir-sofosbuvir (effective 1/1/2026).
    Formulary status terms
    NFNon‑Formulary — denotes drugs removed from the formulary and no longer covered under the plan; listed as 'NF'.
    TierTier — indicates the drug's formulary placement/cost‑sharing level; current and new tiers are shown when changes occur.
    PAPrior Authorization (PA) — drugs listed with 'PA' require prior authorization submitted and approved by Independent Health for coverage.

    This document summarizes upcoming formulary updates including status changes (e.g., Non‑Formulary (NF) designations), tier reassignments, and administrative flags such as PA (prior authorization) and ST (step therapy). Entries list the affected product presentation, prior status, the change type and effective date, any indicated PA or ST requirement, and specified substitution or alternative agents where provided.

    The listings cover a broad set of therapeutic classes—biologics and biosimilars, hepatitis C antivirals, CNS/sleep agents, opioid and neuropathic agents, contraceptives, and oral hypoglycemics—showing the new formulary placement (Tier or NF), whether PA or ST applies, and the effective date for each change. Where the entry provides alternatives, those mappings represent the formulary‑preferred or suggested substitutions that providers should consider when selecting therapy.

    Providers should note and document the exact formulation and the effective date shown for each product when managing prescriptions and authorization requests: the presence of a PA flag requires submission and Independent Health approval for coverage, and products listed as NF after the effective date will not be covered except via an approved medical exception.

    Provider Actions: Prior Authorization, Step Therapy, and Denials

    Prior Authorization

    Prior Authorization Required

    Prior Authorization (PA) remains required for drugs listed with a 'PA' in the change listings. Providers must submit a prior authorization request (or medical exception request) to Independent Health for coverage of any drug flagged 'PA'. Do not assume PA is removed when a tier changes — review the specific drug entry.

    • Affected examples: Cibinqo (all strengths) retain PA with the tier changes (see Tier Changes entries).
    • Posaconazole (suspension and 100 mg tablet) are noted with PA after tier adjustments — PA is required. (See posaconazole entries.)
    • Nitisinone (multiple strengths) entries include PA on new tiers — PA is required for these products.
    Prior Authorization

    PA Remains Required Where Listed

    Prior authorization continues to apply where listed even when products change tiers or status. Several products moving tiers still require PA both before and after the change; providers must follow existing PA rules and submit required documentation.

    Step Therapy Tables and Preferred Alternatives

    ProductStep Therapy (ST) FlagPrevious Step Requirement / Preferred Alternative
    Victoza (liraglutide)
    ST
    Previously required step therapy; listed alternative = liraglutide
    Listed ProductMapped Preferred Alternative(s)Effective Date / Tier note
    Epclusa (various strengths / packs)
    Mavyret; sofosbuvir-velpatasvir; ledipasvir-sofosbuvir
    1/1/2026; tier changes noted in source (various packs moved between Tier 2/3)
    Affected stimulant / ADHD productPreferred alternative(s) / implied stepEffective Date / Tier change
    Lisdexamfetamine (capsules, chewables; multiple strengths)
    amphetamine-dextroamphetamine (tablets & ER), dextroamphetamine (tablets & ER), dexmethylphenidate (tablets & ER), methylphenidate CD ER (capsule/tablet/chewable)
    9/1/2025; moved from Tier 1 to Tier 3 in many strengths
    ProductPlanned change (placement/tier)Effective date (impact)
    Erythromycin base 250 mg delayed‑release capsule
    Current Tier = 1 → New Tier = 3
    Effective 7/1/2026

    Biosimilar and Specialty Biologic Formulary Changes

    Billing Rule

    Verify Abrilada (adalimumab biosimilar) SKU tier and PA status

    Abrilada (adalimumab biosimilar) presentations are listed with Drug Formulary group assignments and some pack sizes retain Tier 2 with 'PA' while other Abrilada SKUs are shown as 'NF'; verify the specific Abrilada SKU's tier and PA status before prescribing or billing.

    • Abrilada 40mg/0.8ml autoinjector and 20mg/0.4ml syringe entries show Tier 2 with PA for certain pack sizes and NF for others effective 1/1/2026.
    • Confirm whether a given Abrilada SKU is NF or requires PA prior to dispensing or submitting a claim.

    Definitions and Key Terms

    Formulary status definitions
    Non‑Formulary (NF)Drugs removed from the formulary and no longer covered under the plan; may trigger claim denial without an approved exception.
    TierDesignates formulary placement and member cost‑sharing; changes list prior and new tier assignments and effective dates.
    PA (Prior Authorization)Indicates the drug requires prior authorization; a provider must submit a PA request for coverage approval.
    Substitution mapping definition
    DefinitionSubstitution mapping — the association of a listed product with one or more alternative/formulary agents suggested as preferred replacements.
    PurposeUsed to indicate preferred therapeutic alternatives or step requirements when a product's tier changes or it becomes NF.

    Policy Revision History and Material Changes

    2026-07-01non-formulary

    Sancuso patch and multiple Relistor formulations (injections, prefilled syringes, tablets), Symproic 0.2 mg, and Xarelto 2.5 mg are scheduled to change to Non‑Formulary effective 7/1/2026.

    2026-07-01tier_change

    Erythromycin base 250 mg delayed‑release capsule and doxylamine‑pyridoxine delayed‑release tablet are scheduled to move from Tier 1 to Tier 3 effective 7/1/2026.

    2026-03-01non-formulary
    Policy Summary
    PayerIndependent Health
    PolicyFormulary (List of Covered Drugs) Changes
    Policy CodePolicy N/A
    Change TypeMultiple NF and tier revisions with PA and ST adjustments
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for drugs flagged 'PA' before requesting coverage.
    SourceLink
    On This Page
    Coverage Criteria and Formulary StatusProvider Actions: Prior Authorization, Step Therapy, and DenialsStep Therapy Tables and Preferred AlternativesBiosimilar and Specialty Biologic Formulary ChangesDefinitions and Key TermsPolicy Revision History and Material Changes
  1. Many specialty and hepatitis C products (e.g., Epclusa, Sovaldi, Epclusa packs) show PA in both prior and new tier rows — submit PA per current criteria.
  2. Stelara and multiple Revlimid strengths were previously PA and are now designated NF; PA remains relevant for clinical exception requests.
  3. Cibinqo entries explicitly list PA on both Tier 2 and Tier 3 effective dates — ensure PA is included with any authorization request.
  4. Prior Authorization

    Prior Authorization Additions

    New prior authorization assignments have been added for selected products. When a drug is newly assigned PA in the change listing, providers must obtain PA before the plan will cover the medication.

    • Posaconazole suspension and posaconazole 100 mg tablets are newly listed with PA effective 1/1/2026 (moved from 9/1/2025 entries).
    • Nitisinone formulations (2 mg, 5 mg, 10 mg, 20 mg) show PA assignments across impacted formularies and effective dates — follow PA rules.
    • Examples of other products newly shown as NF may still require PA for medical exceptions (e.g., Stelara entries).
    Denial Risk

    Non‑Formulary Triggers Denial

    Non-Formulary (NF) designations will result in coverage denial under the formulary benefit unless a medical exception is approved. Providers should expect denied claims when the drug is designated NF as of the listed effective date unless an approved exception is on file.

    • Drugs listed as 'NF' (for example: Stelara effective 7/1/2025; multiple Revlimid strengths effective 10/1/2025; many entries effective 1/1/2026) will no longer be covered under the formulary.
    • If an alternative formulary drug is available, those alternatives are listed in the change entries — consider switching to the listed alternative prior to submitting an exception.
    • For NF drugs, submit a medical exception request with supporting clinical documentation if coverage is medically necessary.
    Step Therapy

    Step Therapy (ST) Applies

    Step Therapy (ST) applies where indicated. When a drug is listed with 'ST' in the change details, providers must ensure step therapy requirements are met or submit documentation supporting an exception.

    • Victoza is listed as ST prior to becoming NF — follow existing step therapy rules until the NF date (Victoza NF 10/1/2025).
    • Sancuso transdermal patch is listed with ST prior to NF — ensure step requirements are met prior to 7/1/2026.
    • If a product retains ST on the new tier, continue to follow step edits when prescribing and authorizing.
    Note

    Preferred Alternatives / Substitution Mapping

    Preferred alternatives and substitution options are listed for many changed drugs. When a non‑preferred or NF product has an indicated alternative, consider the listed alternatives prior to seeking an exception.

    • Hepatitis C: Epclusa and Sovaldi entries list preferred alternatives such as Mavyret, sofosbuvir‑velpatasvir, or ledipasvir‑sofosbuvir — use preferred agents when clinically appropriate.
    • Stelara and multiple biologics: Alternatives listed include adalimumab, Yesintek, Selarsdi, Rinvoq, Xeljanz, Skyrizi, Taltz, Otezla, Entyvio, Actemra, Kevzara, Zeposia, Orencia.
    • For stimulant/ADHD products (e.g., lisdexamfetamine moving to Tier 3), alternatives include amphetamine‑dextroamphetamine, dextroamphetamine, dexmethylphenidate, and methylphenidate formulations.
    Documentation Required

    Record Effective Date for Requests and Counseling

    Document the effective dates and PA/ST status when submitting prior authorization or counseling members. Recordkeeping of the change effective date is essential because coverage, PA, ST, and NF statuses are date‑dependent.

    • Examples: Cibinqo tier and PA changes are effective 1/1/2026 — ensure authorization requests reflect the correct effective date.
    • Multiple posaconazole and nitisinone entries show effective date 1/1/2026 — verify member coverage and PA requirements on or after that date.
    • Keep copies of submitted PA and clinical documentation tied to the date of service and the effective date of the formulary change.
    Note

    Provider Operational Reminders

    Action items and general provider obligations: verify formulary status and PA/ST requirements at the point of prescribing; consider listed alternatives before seeking exceptions; submit full clinical documentation with PA/exception requests; expect denials for NF drugs absent an approved exception.

    • Check the member's specific drug formulary and benefit prior to dispensing or authorizing.
    • For PA submissions include indication, prior therapies, clinical rationale, and relevant lab or diagnostic results.
    • When an alternative is listed, first discuss substitution with the member and prescribing clinician to avoid unnecessary exceptions or denials.
    Where shownMapping entries appear alongside product changes (examples: Epclusa and Sovaldi mapped to Mavyret or sofosbuvir-velpatasvir).

    Multiple opioid and analgesic extended‑release products (including tramadol ER biphasic 300 mg, various morphine ER strengths, codeine sulfate tablets, and related items) and select neuropathic agents (gabapentin once‑daily and Horizant formulations) were changed to Non‑Formulary effective 3/1/2026.

    2026-03-01tier_change

    Gabapentin once‑daily 300 mg and 600 mg, Horizant 300/600 mg, and several butalbital‑acetaminophen formulations had tier increases and NF designation effective 3/1/2026.

    2026-03-01tier_change

    Memantine 2 mg/mL oral solution and disulfiram 250 mg tablets have updated effective dates for tier assignments (document lists 3/1/2026 for these items).

    2026-01-01non-formulary

    A large set of branded biologics and biosimilars (including many adalimumab presentations, Abrilada, Cosentyx, Cimzia, Humira, and others) and numerous antiviral and specialty agents were changed to Non‑Formulary effective 1/1/2026 with listed alternatives.

    2026-01-01non-formulary

    Jynarque (tolvaptan) product presentations, Orladeyo (110 mg and 150 mg), Noxafil packet, Dayvigo 5 mg/10 mg, Quviviq, Wakix, Xyrem and multiple hepatitis C product packs/tablets (Epclusa, Harvoni, Sovaldi, Vosevi) were designated Non‑Formulary or had tier/PA revisions effective 1/1/2026.

    2026-01-01tier_change

    Numerous tier adjustments effective 1/1/2026 affect stimulants, dermatology agents, antifungals (posaconazole), sapropterin, nitisinone, fenofibrate products, griseofulvin formulations and many others; some entries add or retain prior authorization requirements.

    2025-10-01non-formulary

    Victoza (liraglutide listed as alternative) and multiple Revlimid tablet strengths were removed from the formulary (changed to Non‑Formulary) effective 10/1/2025.

    2025-07-01non-formulary

    Stelara was removed from the formulary (changed to Non‑Formulary) effective 7/1/2025 with listed alternatives (Yesintek, Selarsdi, adalimumab, Otezla, Skyrizi, Taltz, Rinvoq, Xeljanz/XR).

    2025-09-01tier_change

    Multiple stimulant and methylphenidate ER LA products and related formulations were reassigned between tiers (many moving to Tier 3) with effective date 9/1/2025.

    2024-05-01document_dateLatest

    Document current as of 2026-05-01 (source file date noted in brief).